Sinoveda's Botanical Drug Approach to Treat Long Covid
Sinoveda is a health brand that is bringing innovative, herbally-based precision to drug discovery. The company's research team, led by co-founders Dr. Nuzhat Tam-Zaman and Dr. Yun K. Tam, has created their patented pharmaceutical platform technology (PPT), which they use to study herbs with a historical record of efficacy.
Through the use of the AI and machine learning-powered PPT framework, Sinoveda seeks to understand why traditional healing plants have their unique effects. Rather than isolate individual components, this research is used to identify, develop, and standardize novel combination therapies which tap into the synergistic potency only found in nature.
The symptoms of Long Covid are varied and numerous, including shortness of breath, fatigue, and cognitive impairment. Dr. Nuzhat explains that the brand's new formula has anti-inflammatory, anti-viral, anti-thrombotic, anti-fibrotic, and immunomodulation properties. This allows it to address a wide variety of symptoms however these may present themselves.
Preliminary human observations have been encouraging. 24 subjects with COVID and Long COVID responded positively to 11 symptoms within two days of treatment. However, further clinical trials are required to establish the safety and effectiveness of SCI-2213. The goal is to develop this botanical pharmaceutical into a safe and effective treatment for Long Covid. To this end, a proper clinical trial is being planned to test the efficacy and safety of SCI-2213.
As clinical trials take place and Sinoveda moves to launch the product in the U.S. and Canada.